Skip to main content

Consumer Reports Rates Best Sunscreen Buys


May 25, 2012 — With any luck, the Memorial Day weekend will bring weather good enough to be slathering on the sunscreen at least every two hours when outdoors.
And to know which are the best products to put on your skin during the unofficial start of summer, the May issue ofConsumer Reports rated 18 top-selling sunscreens. The products ranged from SPF 30 to SPF 75+ and were lotions, sprays, or a spray foam. They varied in price from a low of $.59 an ounce to a high of $20.59 per ounce.
To judge the performance of each product, sunscreens were tested on people, and the ultraviolet B (UVB) radiation protection was rated before and after swimming in fresh water for up to 80 minutes. Testers also checked whether the product stained clothing.
In addition, they did a new "critical wavelength" test required by the FDA to see if the sunscreen truly offered broad-spectrum UVA and UVB protection. UVB radiation is the main cause of sunburn, while UVA rays penetrate deeper, where they can cause long-term damage and age skin.
Top 7 Sunscreens
Most products offered good UVB protection, while many helped block UVA rays.
The cheapest sunscreen outscored the most expensive product in the test, leading researchers to conclude that "price had nothing to do with performance."
After testing, Consumer Reports named three of its highest-rated sunscreens as "Best Buys," while four other top-scoring products were "Recommended."
Best Buys
  • No-Ad lotion with aloe &vitamin E, SPF 45, $.59/ounce
  • Walgreens continuous spray sport, SPF 50, $1.30/ounce
  • Coppertone oil-free foaming spray, SPF 75+, $1.67/ounce
Recommended
  • All Terrain Aqua Sport lotion, SPF 30, $4/ounce
  • Banana Boat clear ultra-mist sports performance active dry protect spray, SPF 30, $1.63/ounce
  • Coppertone sport high performance ultra sweat-proof spray, SPF 30, $1.67/ounce
  • Eco all natural sunscreen body lotion, SPF 30, $4.72/ounce
Two sunscreens flunked the "broad spectrum" test:
  • Alba Botanical natural very emollient sunblock sport, SPF 45
  • Banana Boat Kids tear-free, sting-free, SPF 50+
No matter which product you put on, Consumer Reports offered these tips to help stay safe in the sun:
  • Choose a waterproof sunscreen with at least an SPF of 30. Above 30 provided little extra protection.
  • Use 2 to 3 tablespoons of sunscreen; reapply every two hours and after swimming or sweating.
  • Wear a hat and protective clothing in addition to using sunscreen.
  • The FDA is looking into possible risks of inhaling spray sunscreens. Consumer Reports recommends avoiding using sprays on kids. If used, spray on hands first before applying to the face.
  • The group also recommends that pregnant women may want to avoid products with retinyl palmitate.
Read labels and ingredients carefully. New FDA requirements for sunscreens and other cosmetic products containing an SPF value will soon make it easier for consumers to understand the labels and what claims, such as "broad spectrum" or "water-resistance," really mean.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more